170 related articles for article (PubMed ID: 37005910)
41. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Huang TC; Lin CC; Wu YC; Chia-Hsien Cheng J; Lee JM; Wang HP; Huang PM; Hsu FM; Yeh KH; Cheng AL; Tzen KY; Hsu CH
J Formos Med Assoc; 2019 Jun; 118(6):1024-1030. PubMed ID: 30502100
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Significance of Stratification Using Pathological Stage and Response to Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Matsuda S; Kawakubo H; Okamura A; Takahashi K; Toihata T; Takemura R; Mayanagi S; Takeuchi H; Watanabe M; Kitagawa Y
Ann Surg Oncol; 2021 Dec; 28(13):8438-8447. PubMed ID: 34142294
[TBL] [Abstract][Full Text] [Related]
43. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Okunaka M; Kotani D; Demachi K; Fujiwara H; Sakashita S; Yoshino T; Fujita T; Kojima T
Esophagus; 2022 Apr; 19(2):240-249. PubMed ID: 34611830
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Suzuki T; Okamura A; Watanabe M; Mine S; Imamura Y; Asari T; Osumi H; Nakayama I; Ichimura T; Ogura M; Ooki A; Takahari D; Yamaguchi K; Chin K
Ann Surg Oncol; 2020 May; 27(5):1510-1517. PubMed ID: 31820213
[TBL] [Abstract][Full Text] [Related]
45. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
46. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
47. PES1 reduces CD8
Ma N; Hua R; Yang Y; Liu ZC; Pan J; Yu BY; Sun YF; Xie D; Wang Y; Li ZG
J Biomed Sci; 2023 Mar; 30(1):20. PubMed ID: 36959575
[TBL] [Abstract][Full Text] [Related]
48. ZNF750 Expression as a Novel Candidate Biomarker of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma.
Otsuka R; Akutsu Y; Sakata H; Hanari N; Murakami K; Kano M; Takahashi M; Matsumoto Y; Sekino N; Yokoyama M; Iida K; Matsubara H
Oncology; 2017; 93(3):197-203. PubMed ID: 28558382
[TBL] [Abstract][Full Text] [Related]
49. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
[TBL] [Abstract][Full Text] [Related]
50. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
51. Integrated molecular characterization of esophageal basaloid squamous cell carcinoma: a subtype with distinct RNA expression pattern and immune characteristics, but no specific genetic mutations.
Li Y; Liu L; Pan Y; Fang F; Xie T; Cheng N; Guo C; Xue X; Zeng H; Xue L
J Pathol; 2023 Feb; 259(2):136-148. PubMed ID: 36371676
[TBL] [Abstract][Full Text] [Related]
52. Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma.
Sekino N; Kano M; Kobayashi S; Murakami K; Sakata H; Toyozumi T; Endo S; Matsumoto Y; Suito H; Takahashi M; Otsuka R; Yokoyama M; Shiraishi T; Okada K; Kamata T; Ryuzaki T; Hirasawa S; Kinoshita K; Sasaki T; Iida K; Komatsu A; Matsubara H
Oncology; 2022; 100(5):267-277. PubMed ID: 35134807
[TBL] [Abstract][Full Text] [Related]
53. The clinical impact of angiotensin-(1-7)/mitochondrial assembly receptor axis in esophageal squamous cell carcinoma patients receiving curative esophagectomy.
Chen YH; Lu HI; Lo CM; Huang CC; Hsiao CC; Li SH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):310-318. PubMed ID: 31202501
[TBL] [Abstract][Full Text] [Related]
54. Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma.
Yang Y; Huang X; Zhou L; Deng T; Ning T; Liu R; Zhang L; Bai M; Zhang H; Li H; Ba Y
BMC Cancer; 2019 May; 19(1):526. PubMed ID: 31151431
[TBL] [Abstract][Full Text] [Related]
55. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
56. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
[TBL] [Abstract][Full Text] [Related]
57. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
[TBL] [Abstract][Full Text] [Related]
58. Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
Kono K; Mimura K; Yamada R; Ujiie D; Hayase S; Tada T; Hanayama H; Min AKT; Shibata M; Momma T; Saze Z; Ohki S
Esophagus; 2018 Jan; 15(1):1-9. PubMed ID: 29892809
[TBL] [Abstract][Full Text] [Related]
59. Preoperative squamous cell carcinoma antigen and albumin serum levels predict the survival of patients with stage T1-3N0M0 esophageal squamous cell carcinoma: a retrospective observational study.
Wu LL; Liu X; Huang W; Lin P; Long H; Zhang LJ; Ma GW
J Cardiothorac Surg; 2020 May; 15(1):115. PubMed ID: 32456707
[TBL] [Abstract][Full Text] [Related]
60. Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Okamura A; Matsuda S; Mayanagi S; Kanamori J; Imamura Y; Irino T; Kawakubo H; Mine S; Takeuchi H; Kitagawa Y; Watanabe M
Ann Surg Oncol; 2021 Feb; 28(2):1209-1216. PubMed ID: 32524457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
